Novartis AG
Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer
Last updated:
Abstract:
The present application n relates to a pharmaceutical composition comprising a PD-1 antibody and an M-CSF antibody. The combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer.
Status:
Grant
Type:
Utility
Filling date:
27 Jul 2016
Issue date:
11 May 2021